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1 Introduction
Human immunodeficiency virus (HIV) infects cells by endocytosis and takes over parts
of the cell’s reaction pathways in order to reproduce itself and spread the infection. One
such pathway taken over by HIV becomes the inflammatory pathway which uses Nuclear
Factor κB (NF-κB) as the principal transcription factor. Therefore, knocking out the NF-
κB pathway would prevent HIV from reproducing itself. In this report, our goal is to
produce a simple model for this pathway with which we can identify potential targets for
anti-HIV therapies and test out various hypotheses.
In the nucleus of the cell, NF-κB runs along a strand of DNA and produces an NF-κB
inhibitor (IκB). IκB is transported from the nucleus into the cytoplasm where it forms a
complex with cytoplasmic NF-κB. The complex is degraded by IκB kinase (IκK), and, in the
process, the IκB component of the complex is destroyed. IκK exists in various forms within
the cytoplasm and is converted from its inactive form to its active form in the presence
of Tumour Necrosis Factor (TNF). Thus, a possible strategy for treating HIV would be
to decrease the amount of IκK in the cytoplasm, which would reduce the degradation of
NF-κB−IκB complexes. Since the NF-κB cannot enter the nucleus while it is in one of these
complexes, it cannot participate in the HIV reproduction cycle.
Previous models for the inflammatory pathway have been proposed. Hoffmann et al. [1]
modelled this pathway using 24 ordinary differential equations (ODEs) and 49 parameters.
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The model explicitly tracked three forms of IκB (α, β, and ), showing that IκBα provided
the main negative feedback to turn off the NF-κB response, while the other two forms
played stabilizing roles over longer times. This model was amended by Lipniacki et al. [4]
who, among other things, focused only on the α form of IκB; their model had 15 ODEs and
30 parameters. Kearns et al. [2] expanded the model of [1] with an additional description of
the transcription of IκBβ and IκB. All of these models contain large numbers of variables
and parameters. In contrast to these large models, Krishna et al. [3] investigated a minimal
model with 3 ODEs and 5 (dimensionless) parameters and showed that it produced spiky
oscillations.
Following these lines of research, in Section 2, we present a very simple model with
four coupled first-order ODEs and see what happens if we treat IκK concentration as a
parameter that can be controlled (by some unspecified means). In Section 3, we augment
this model to account for activation and deactivation of IκK, which is controlled (again, by
some unspecified means) by TNF.
2 A simple first model
In this section, we start by formulating a simple model for the NF-κB pathway. A
cartoon of the pathway that we consider is shown in Figure 1. We suppose that cytoplasmic
NF-κB is transferred in and out of the nucleus at rates k1 and k−1, respectively. Inside the
nucleus, two NF-κB molecules work as catalysts for producing transcripts from genes in
the DNA to produce IκB in the nucleus at a rate k2, without using up any of the NF-κB.
IκB is transported out of the nucleus into the cytoplasm at a rate k3, where it reacts with
the NF-κB at a rate k4 to form a stable complex. In this complex form, NF-κB cannot
enter the nucleus. However, in the presence of IκK, the complex is broken down, the IκB
component is destroyed, and NF-κB is released at rate k5.
Thus we have the following chemical reactions (note that these are not conventional
chemical reaction equations because some chemical species are not conserved):
NF-κBc
k1

k−1
NF-κBn (2.1)
2NF-κBn +DNA
k2−→ IκBn + 2NF-κBn +DNA (2.2)
IκBn
k3−→ IκBc (2.3)
IκBc + NF-κBc
k4−→ NF-κB−IκBc (2.4)
NF-κB−IκBc + IκKc k5−→ NF-κBc + IκKc (2.5)
where the subscripts c and n indicate whether the species is in the cytoplasm or in the
nucleus, respectively. Initially, we included the reverse reaction in (2.2) with rate k−2,
but decided to set k−2 = 0 because k−2  k2. We assume that each reaction progresses
according to the law of mass action. We denote the concentration of NF-κB by A, the
concentration of IκB by B, the concentration of NF-κB−IκB complex by C, and the con-
centration of IκK by D. For simplicity, we suppose that D is constant. The evolution
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Figure 1 Cartoon of a simple version of the NF-κB pathway
equations for the concentrations of the chemical species are
dAc
dt
= k−1An − k1Ac − k4AcBc + k5DCc, (2.6)
dAn
dt
= −k−1An + k1Ac, (2.7)
dBc
dt
= k3Bn − k4AcBc, (2.8)
dBn
dt
= k2A
2
n − k3Bn, (2.9)
dCc
dt
= k4AcBc − k5DCc. (2.10)
Adding (2.6), (2.7), and (2.10), we find that
d(Ac +An + Cc)
dt
= 0, (2.11)
i.e., the total amount of NF-κB is conserved, which corresponds to biochemical reality over
the timescale of events we consider (a few days). Denoting the total amount of NF-κB by
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A∗, we can remove An from the system, to leave us with
dAc
dt
= k−1A∗ − (k−1 + k1 + k4Bc)Ac − (k−1 − k5D)Cc, (2.12)
dBc
dt
= k3Bn − k4AcBc, (2.13)
dBn
dt
= k2(A
∗ −Ac − Cc)2 − k3Bn, (2.14)
dCc
dt
= k4AcBc − k5DCc. (2.15)
Although we have eliminated An from the system, it is convenient to express the steady
state in terms of An (= A
∗ −Ac − Cc) as follows:
Ac =
k−1
k1
An, Bc =
k1k2
k−1k4
An, Bn =
k2
k3
A2n, Cc =
k2
k5D
A2n. (2.16)
If all of the rate constants are positive, then Ac and Bc are positive only if An is positive.
In terms of An, the constraint A
∗ = An +Ac + Cc becomes
A∗ =
(
1 +
k−1
k1
)
An +
k2
k5D
A2n. (2.17)
For any given positive values of A∗, D, and the ki’s, it is evident that equation (2.17)
has a unique nonnegative solution An. Therefore, our system has a unique physical (i.e.,
nonnegative) solution for all positive parameter values.
We now nondimensionalise the system (2.12)–(2.15) by setting
Ac =
k−1
k3
A∗A′c, Bc,n =
k2A
∗2
k3
B′c,n, Cc = A
∗C ′c, t =
1
k3
t′. (2.18)
The resulting equations (dropping the primes) are
dAc
dt
= 1− (a−1 + a1 + a4Bc)Ac − (1− a5)Cc, (2.19)
dBc
dt
= Bn − a4
a2
AcBc, (2.20)
dBn
dt
= (1− a−1Ac − Cc)2 −Bn, (2.21)
dCc
dt
= a−1(a4AcBc − a5Cc), (2.22)
where a−1 = k−1/k3, a1 = k1/k3, a2 = k2A∗/k−1, a4 = k2k4A∗2/k23, and a5 = k5D/k−1.
Note that the rate constants, k4 and k5 have dimensions µM
−1s−1, whereas the remaining
rate constants have dimension s−1.
We now introduce the parameter values given in Table 1 into the above equations and
solve them numerically. The results (with D, the IκK concentration, set to 1 µM) are shown
in Figure 2. We see that the system settles down to its steady state within three days, but
we observe that there is an initial transient followed by a slow decay.
In Figure 3, we consider the effect of doubling the amount of IκK and the effect of
removing all the IκK from the system. Note that in the latter case, the equations (2.16)
and (2.17) are no longer valid because of the zero divisor, D ≡ 0. We see that doubling the
amount of IκK results in an increase in the steady state amount of IκB both in the nucleus
and in the cytoplasm, with a small increase in the amount of cytoplasmic NF-κB. This is
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Parameter Value Units Source
A∗ 0.1 µM [2]
k−1 8 ×10−5 s−1 [2]
k1 0.09 s
−1 [2]
k−2 0 s−1 [2]
k2 1.6 ×10−2 s−1 [1]
k3 2 ×10−4 s−1 [2]
k4 0.5 µM
−1s−1 [2]
k5 1.13 ×10−4 µM−1s−1 S. Qazi
Table 1 Parameter values for system (2.12)–(2.15). The value for k5 was provided by S.
Qazi (problem presenter).
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Figure 2 Numerical solution of the system (2.12)–(2.15), using the parameters from Table
1. The system reaches a steady state within ≈ 3 days.
coupled with a small decrease in the amount of the complex NF-κB. Removing all of the
IκK results in the complete removal of IκB from the nucleus, because in the absence of IκK,
all of the NF-κB is bound in the complex in the cytoplasm, and hence the transcription in
the nucleus cannot be activated.
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Figure 3 Numerical solution of the system (2.12)–(2.15), using parameters from Table 1.
The amount of IκK is doubled at day 8 and is removed at day 16.
We also examined the stability of the fixed point of the system (2.12)–(2.15). We found
that the Jacobian matrix evaluated at this point has positive determinant and negative trace
for all positive parameter values, but we could not confirm that all eigenvalues had negative
real parts in general. Using the values given in Table 1, we evaluated the eigenvalues of the
Jacobian numerically for several values of D ranging from 0.001 up to 2.0. In each case,
all four eigenvalues had negative real parts, i.e., the fixed point was stable. For the smaller
values of D, all four eigenvalues were real; for larger values, two of the eigenvalues were
complex.
If the variable D, representing IκK, is viewed as a control parameter, then we observe
that the interesting limit D → 0 could be interpreted as a singular control problem. How-
ever, since IκK is a cytoplasmic molecule, it is not directly controllable from outside the
cell. Therefore, this simple model isolates the importance of IκK, but a variable controlling
it needs to be incorporated into the model. At this stage, we modify our model so that the
concentration of IκK is not constrained to be a constant. This modified model is described
in the next section.
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Figure 4 Cartoon showing more complicated version of the NF-κB pathway
3 Second model: Tracking the concentration of IκK
Focussing on the IκK part of the reaction network, we ask how the concentration of
IκK can vary. As noted in the introduction, IκK exists in various forms. The active form of
IκK (denoted IκKa) is responsible for breaking down the NF-κB–IκB complex, but becomes
inactive during the process (turning into IκKi). The active form is produced in the presence
of TNF from its neutral form IκK0, which is always present. A revised cartoon is shown in
Figure 4. The reaction scheme now is given by
NF-κBc
k1

k−1
NF-κBn (3.1)
2NF-κBn +DNA
k2−→ IκBn + 2NF-κBn +DNA (3.2)
IκBn
k3−→ IκBc (3.3)
IκBc + NF-κBc
k4−→ NF-κB−IκBc (3.4)
NF-κB−IκBc + IκKa k5−→ NF-κBc + IκKi (3.5)
TNF + IκK0
k6

k−6
TNF + IκKa (3.6)
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We suppose that IκK0 is produced at the constant rate kp and degrades at the rate `0, and
that IκKi degrades at the rate `i. It is known that TNF, which influences the rates in the
reaction (3.6), is produced outside the cell in response to the HIV infection. Denoting the
concentrations of each of the IκK types as D0, Da, and Di, and the constant concentration
of TNF as T , we have the following system of equations:
dAc
dt
= k−1An − k1Ac − k4AcBc + k5CcDa, (3.7)
dAn
dt
= k1Ac − k−1An, (3.8)
dBc
dt
= k3Bn − k4AcBc, (3.9)
dBn
dt
= k2A
2
n − k3Bn, (3.10)
dCc
dt
= k4AcBc − k5CcDa, (3.11)
dDa
dt
= k6(T )D0 − (k−6(T ) + k5Cc)Da, (3.12)
dD0
dt
= kp + k−6(T )Da − (k6(T ) + `0)D0, (3.13)
dDi
dt
= k5CcDa − `iDi. (3.14)
Note that Di appears only in equation (3.14), so we can solve for Di explicitly in terms
of the other functions. In particular, if the system (3.7)–(3.13) converges to a stable fixed
point, then Di converges to its equilibrium value k5CcD0/`i. For this reason, we omit Di
from further analysis.
We substitute for An = A
∗ − Ac − Cc and nondimensionalise the concentrations and
time in the same way as before, using, in addition, the nondimensionalisations
Da =
kp
k−6
D′a, D0 =
kp
k3
D′0. (3.15)
The resulting equations (dropping the primes) are
dAc
dt
= 1− (a−1 + a1 + a4Bc)Ac + (a∗5Da − 1)Cc, (3.16)
dBc
dt
= Bn − a4
a2
AcBc, (3.17)
dBn
dt
= (1− a−1Ac − Cc)2 −Bn, (3.18)
dCc
dt
= a−1(a4BcAc − a∗5CcDa), (3.19)
dDa
dt
= a6(T )a−6D0 − (a−6 + a7Cc)Da, (3.20)
dD0
dt
= 1− (a6 + `∗0)D0 +Da, (3.21)
where a∗5 = k5kp/k−1k−6, a−6 = k−6/k3, a6 = k6/k3, a7 = k5A∗/k3, and `∗0 = `0/k3, and
ap = kpA
∗/k−6.
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Parameter Value Units Source
k−6 1.5 ×10−3 s−1 [4] / S. Qazi
kp 2.5 ×10−5 s−1 [4]
`0 kp/10 s
−1 S. Qazi
Table 2 Parameter values for the system (3.7)–(3.13), in addition to those appearing in
Table 1. Our definition of k−6 is a bit different from that in [4]. The value for `0 was
provided by S. Qazi (problem presenter).
The values for the new parameters are given in Table 2. In our numerical simulations, we
chose to fix k−6 and to let k6(T ) vary to study the effect of different levels of TNF. Figure 5
shows the results of simulations with each of the fifteen different values k6 = q×10−r where
r ∈ {3, 4, 5} and q ∈ {1, 2, 3, 4, 5}, and another with k6 = 0. The dark blue horizontal line
in each graph represents the solution for k6 = 0. As k6 decreases to 0 thorough our fifteen
nonzero values, the corresponding solutions tend to move towards the k6 = 0 solution. We
observe that some of the graphs in Figure 5 qualitatively resemble published work, e.g. in
[4], see Figure 3F (NF-κB−IκB complex, our Cc) and Figure 9[A,G] (cytoplasmic IκB, our
Bc).
The system (3.7)–(3.13) has a unique rest state for all positive parameter values. To
see this, we set the derivatives equal to 0 and express the solution in terms of Da and the
eliminated variable An as follows:
Ac =
k−1
k1
An, Bc =
k1k2
k−1k4
An, Bn =
k2
k3
A2n, Cc =
k2
k5
A2n
Da
, (3.22)
Da =
kpk6 − k2(k6 + `0)A2n
k−6`0
, D0 =
k−6Da + k2A2n
k6
. (3.23)
Using Cc = A
∗−An−Ac, the relation 0 = −CcDa + k2A2n/k5 [from the last term in (3.22)]
becomes
0 =
[
An
(
1 +
k−1
k1
)
−A∗
] [
kpk6 − k2(k6 + `0)A2n
k−6`0
]
+
k2A
2
n
k5
=: H(An). (3.24)
Thus An is the root of a cubic polynomial H. Let α = [kpk6/(k2(k6 + `0))]
1/2. Since any
physical solution has Da ≥ 0, we see from (3.23) that we are only interested in An in [0, α].
Since H(0) < 0, H(+∞) = −∞, and H(α) > 0, it follows that the cubic polynomial H has
a unique root in [0, α], which is the unique value of An that determines the rest state. In
particular, it can be seen that as k6 decreases to 0, then α decreases to 0 and hence, the
equilibrium value of An also decreases to 0. Therefore, the equilibrium values of Ac, Bc,
Bn, and Da decrease to 0, while Cc = A
∗ − Ac − An increases to A∗ and D0 converges to
kp/`0. These qualitative trends are confirmed in Figure 5.
For the stability analysis, we checked the Jacobian matrix numerically at the rest state
for the same parameter values at which we performed our simulations (Figure 5) (except
for the degenerate case k6 = 0). We found that the system was stable in all cases. More
precisely, for the fifteen nonzero values of k6 examined, all six eigenvalues are negative real
numbers when k6 ≤ 2× 10−4 or k6 = 5× 10−3; for each of the other values, there were four
negative real eigenvalues and two complex eigenvalues with negative real parts.
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Figure 5 The numerical solutions of system (3.16)–(3.21), using parameter values from
Tables 1 and 2 while varying k6. The dark blue horizontal lines are the solutions for
k6 = 0. The other five colours each correspond to solutions for three different values
k6 = q × 10−3, q × 10−4, q × 10−5, with q = 1 (red), q = 2 (black), q = 3 (light blue),
q = 4 (green), and q = 5 (yellow). As k6 decreases to 0, the solutions move monotonically
closer to the k6 = 0 solution. Not all curves are visible because of overlap.
4 Discussion and Conclusions
Persistence and evolution of HIV require virus reproduction and spread. In this report,
we have focussed on the HIV commandeered inflammatory pathway in cells where NF-κB
is the main transcription factor. Thus, one approach to treating HIV is to block this NF-
κB pathway, which plays an important role in HIV reproduction by reproducing the virus’
DNA in the cell nucleus. We investigated two simplified models of this pathway, based
primarily on much larger ODE models that had previously been published. Our simple four
variable model pinpoints how the NF-κB pathway can be blocked. Namely, we find that
IκK plays a crucial role in controlling the amount of free NF-κB in the cytosolic space that
can potentially enter the nucleus to produce more virus DNA. Although it is clear that
control of IκK is a potential anti-HIV target, the four variable model does not allow us to
address the direct control of these molecules. In our second slightly expanded model, we
have been able to capture a reasonable amount of the behaviour observed by others. In
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particular, this second model suggested that a new approach to therapy would be to block
the extracellular production of TNF, or at least to block TNF’s activation of IκK.
A project for future work would be to conduct a more careful sensitivity analysis to
account for uncertainties in the parameter values. We also considered the possibility of
approaching this as a control problem, say with k5 and k6 as control parameters, but it is
not yet clear to us what we wish to minimize or what controls (i.e., drugs) are available.
Another task could be to investigate the larger models studied earlier and see if they can
be systematically reduced to our (second) model by omitting less significant terms.
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